Swapnali Barde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Swapnali Barde has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Tomas Hökfelt
Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
7 shared publications - Jan Mulder
Department of Neuroscience, Karolinska Institutet
4 shared publications Miklos Palkovits
The Hungarian Academy of Sciences, Budapest, Hungary and Human Brain Tissue Bank and Laboratory, Semmelweis University, H-1085, Budapest, Hungary
3 shared publications- Csaba Adori
Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
2 shared publications - Eva Hedlund
Department of Biochemistry and Biophysics, Stockholm University, Svante Arrhenius v. 16C, 106 91 Stockholm, Sweden
2 shared publications - Gustavo Turecki
McGill University
2 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4) , 100269
Targeting ROR1 with KAN571C disrupts resistance networks in mantle cell lymphoma
- 13 July 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4) , 100269
Open AccessTargeting ROR1 with KAN571C disrupts resistance networks in mantle cell lymphoma
- Open Access
HUBMet: An integrative database and analytical platform for human blood metabolites and metabolite-protein associations
Understanding human blood metabolites is essential for deciphering systemic physiology and disease mechanisms, yet remains challenging due to diverse origins and dynamic regulation. In this study, we developed HUBMet ( https://hubmet.app.bio-it.tech/home ), an open-access web server that includes 3,950 metabolites and 129,814 metabolite-protein associations, with four analytical modules: Over-Representation Analysis (ORA) for enrichment analysis; Metabolite Set Enrichment Analysis (MSEA) for quantitative data analysis; Tissue Specificity Analysis (TSA) for assessing metabolite-tissue relevance; Metabolite-Protein Network Analysis (MPNet) for identifying key metabolite-protein associations and functional modules. HUBMet’s utility is demonstrated through a COVID-19 case study revealing metabolic signatures associated with disease severity.
Open AccessHUBMet: An integrative database and analytical platform for human blood metabolites and metabolite-protein associations
Understanding human blood metabolites is essential for deciphering systemic physiology and disease mechanisms, yet remains challenging due to diverse origins and dynamic regulation. In this study, we developed HUBMet ( https://hubmet.app.bio-it.tech/home ), an open-access web server that includes 3,950 metabolites and 129,814 metabolite-protein associations, with four analytical modules: Over-Representation Analysis (ORA) for enrichment analysis; Metabolite Set Enrichment Analysis (MSEA) for quantitative data analysis; Tissue Specificity Analysis (TSA) for assessing metabolite-tissue relevance; Metabolite-Protein Network Analysis (MPNet) for identifying key metabolite-protein associations and functional modules. HUBMet’s utility is demonstrated through a COVID-19 case study revealing metabolic signatures associated with disease severity.
- Open Access
- 29 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Transient expression of the neuropeptide galanin modulates peripheral‑to‑central connectivity in the somatosensory thalamus during whisker development in mice
The significance of transient neuropeptide expression during postnatal brain development is unknown. Here, we show that galanin expression in the ventrobasal thalamus of infant mice coincides with whisker map development and modulates subcortical circuit wiring. Time-resolved neuroanatomy and single-nucleus RNA-seq identified complementary galanin (Gal) and galanin receptor 1 (Galr1) expression in the ventrobasal thalamus and the principal sensory nucleus of the trigeminal nerve (Pr5), respectively. Somatodendritic galanin release from the ventrobasal thalamus was time-locked to the first postnatal week, when Gal1R+ Pr5 afferents form glutamatergic (Slc17a6+) synapses for the topographical whisker map to emerge. RNAi-mediated silencing of galanin expression disrupted glutamatergic synaptogenesis, which manifested as impaired whisker-dependent exploratory behaviors in infant mice, with behavioral abnormalities enduring into adulthood. Pharmacological probing of receptor selectivity in vivo corroborated that target recognition and synaptogenesis in the thalamus, at least in part, are reliant on agonist-induced Gal1R activation in inbound excitatory axons. Overall, we suggest a neuropeptide-dependent developmental mechanism to contribute to the topographical specification of a fundamental sensory neurocircuit in mice.
- 29 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Open AccessTransient expression of the neuropeptide galanin modulates peripheral‑to‑central connectivity in the somatosensory thalamus during whisker development in mice
The significance of transient neuropeptide expression during postnatal brain development is unknown. Here, we show that galanin expression in the ventrobasal thalamus of infant mice coincides with whisker map development and modulates subcortical circuit wiring. Time-resolved neuroanatomy and single-nucleus RNA-seq identified complementary galanin (Gal) and galanin receptor 1 (Galr1) expression in the ventrobasal thalamus and the principal sensory nucleus of the trigeminal nerve (Pr5), respectively. Somatodendritic galanin release from the ventrobasal thalamus was time-locked to the first postnatal week, when Gal1R+ Pr5 afferents form glutamatergic (Slc17a6+) synapses for the topographical whisker map to emerge. RNAi-mediated silencing of galanin expression disrupted glutamatergic synaptogenesis, which manifested as impaired whisker-dependent exploratory behaviors in infant mice, with behavioral abnormalities enduring into adulthood. Pharmacological probing of receptor selectivity in vivo corroborated that target recognition and synaptogenesis in the thalamus, at least in part, are reliant on agonist-induced Gal1R activation in inbound excitatory axons. Overall, we suggest a neuropeptide-dependent developmental mechanism to contribute to the topographical specification of a fundamental sensory neurocircuit in mice.
- Open Access
- 4 November 2023
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 78, 54-63
Substance P, NPY, CCK and their receptors in five brain regions in major depressive disorder with transcriptomic analysis of locus coeruleus neurons
- 4 November 2023
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 78, 54-63
Open AccessSubstance P, NPY, CCK and their receptors in five brain regions in major depressive disorder with transcriptomic analysis of locus coeruleus neurons
- Open Access
Expression of substance P, NPY and their Receptors Is Altered in Major Depression
BACKGROUND: Major depressive disorder (MDD) is a serious disease and a burden to patients, families and society. Rodent experiments and human studies suggest that several neuropeptide systems, including substance P(SP)/tachykinin, neuropeptide Y(NPY) and their G protein-coupled receptors are involved in mood regulation. METHODS: We assessed the transcript levels (qPCR) of SP/tachykinin and NPY systems in five regions from postmortem brains of male and female depressed subjects who committed suicide (DSS) and controls: dorsolateral prefrontal cortex (DLPFC), anterior cingulate cortex (ACC), the dorsal raphe nucleus (DRN), locus coeruleus (LC) and medullary raphe nuclei (MRN). We also analysed human LC neurons isolated using LCM with Smart-seq2 RNA sequencing. RESULTS: Transcripts for all nine members were detected in male and female controls with marked regional variations of the raw CT values and with the highest levels for several tachykinin and tachykinin receptor transcripts in the DRN and for NPY and NPYR transcripts in the PFC regions. Significant sex differences for controls were recorded only in the DRN ( NPYR2 >in females) and LC ( TAC3 and NPY >in females). Elevated expression in DSS was recorded in (i) DLPFC for SP, TAC and TAC3 in females, SP in males, and NPYR1 in both sexes; and (ii) LC for all tachykinin family transcripts in females, SP, TACR1 and TACR3 in males, NPY in both sexes, and NPYR1 in males. CONCLUSIONS: The selective perturbation of neuropeptide systems in MDD patients may assist in the search for novel treatment strategies for subjects afflicted by this grave disorder.
Open AccessExpression of substance P, NPY and their Receptors Is Altered in Major Depression
BACKGROUND: Major depressive disorder (MDD) is a serious disease and a burden to patients, families and society. Rodent experiments and human studies suggest that several neuropeptide systems, including substance P(SP)/tachykinin, neuropeptide Y(NPY) and their G protein-coupled receptors are involved in mood regulation. METHODS: We assessed the transcript levels (qPCR) of SP/tachykinin and NPY systems in five regions from postmortem brains of male and female depressed subjects who committed suicide (DSS) and controls: dorsolateral prefrontal cortex (DLPFC), anterior cingulate cortex (ACC), the dorsal raphe nucleus (DRN), locus coeruleus (LC) and medullary raphe nuclei (MRN). We also analysed human LC neurons isolated using LCM with Smart-seq2 RNA sequencing. RESULTS: Transcripts for all nine members were detected in male and female controls with marked regional variations of the raw CT values and with the highest levels for several tachykinin and tachykinin receptor transcripts in the DRN and for NPY and NPYR transcripts in the PFC regions. Significant sex differences for controls were recorded only in the DRN ( NPYR2 >in females) and LC ( TAC3 and NPY >in females). Elevated expression in DSS was recorded in (i) DLPFC for SP, TAC and TAC3 in females, SP in males, and NPYR1 in both sexes; and (ii) LC for all tachykinin family transcripts in females, SP, TACR1 and TACR3 in males, NPY in both sexes, and NPYR1 in males. CONCLUSIONS: The selective perturbation of neuropeptide systems in MDD patients may assist in the search for novel treatment strategies for subjects afflicted by this grave disorder.
- Open Access
- 23 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (30)
Disorganization and degeneration of liver sympathetic innervations in nonalcoholic fatty liver disease revealed by 3D imaging
3D imaging reveals gradual degeneration of liver sympathetic nerves in human and experimental nonalcoholic fatty liver disease.
- 23 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (30)
Open AccessDisorganization and degeneration of liver sympathetic innervations in nonalcoholic fatty liver disease revealed by 3D imaging
3D imaging reveals gradual degeneration of liver sympathetic nerves in human and experimental nonalcoholic fatty liver disease.
- 9 December 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 113 (52) , E8472-E8481
Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide
Significance: Depression is a seriously disabling disorder, twice as common in women as in men. Lack of efficacy of existing pharmacotherapies in subsets of patients has led to an intensive search for new targets for antidepressant development, including receptors for neuropeptides such as galanin (GAL). In this study, we explore GAL and its three receptors, GAL1–3, comparing postmortem brain regions from depressed suicide patients and controls. Using quantitative PCR and bisulfite pyrosequencing, we report significant changes in the transcript and DNA methylation levels ofGALand galanin receptor 3 (GALR3) in the locus coeruleus and dorsal raphe nucleus, two regions important for mood regulation. Our findings suggest GAL3involvement in depressive disorder, making it a possible drug target for this disease.
- 9 December 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 113 (52) , E8472-E8481
Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide
Significance: Depression is a seriously disabling disorder, twice as common in women as in men. Lack of efficacy of existing pharmacotherapies in subsets of patients has led to an intensive search for new targets for antidepressant development, including receptors for neuropeptides such as galanin (GAL). In this study, we explore GAL and its three receptors, GAL1–3, comparing postmortem brain regions from depressed suicide patients and controls. Using quantitative PCR and bisulfite pyrosequencing, we report significant changes in the transcript and DNA methylation levels ofGALand galanin receptor 3 (GALR3) in the locus coeruleus and dorsal raphe nucleus, two regions important for mood regulation. Our findings suggest GAL3involvement in depressive disorder, making it a possible drug target for this disease.
- Open Access
- 1 January 2015
- Published by SAGE Publications in Molecular Pain
- Vol. 11, 44
G Protein-Gated Inwardly Rectifying Potassium Channel Subunits 1 and 2 are Down-Regulated in Rat Dorsal Root Ganglion Neurons and Spinal Cord after Peripheral Axotomy
Background: Increased nociceptive neuronal excitability underlies chronic pain conditions. Various ion channels, including sodium, calcium and potassium channels have pivotal roles in the control of neuronal excitability. The members of the family of G protein-gated inwardly rectifying potassium (GIRK) channels, GIRK1–4, have been implicated in modulating excitability. Here, we investigated the expression and distribution of GIRK1 and GIRK2 in normal and injured dorsal root ganglia (DRGs) and spinal cord of rats. Results: We found that ~70% of the DRG neurons expressed GIRK1, while only <10% expressed GIRK2. The neurochemical profiles of GIRK1- and GIRK2-immunoreactive neurons were characterized using the neuronal markers calcitonin gene-related peptide, isolectin-B4 and neurofilament-200, and the calcium-binding proteins calbindin D28k, calretinin, parvalbumin and secretagogin. Both GIRK subunits were expressed in DRG neurons with nociceptive characteristics. However, while GIRK1 was widely expressed in several sensory neuronal subtypes, GIRK2 was detected mainly in a group of small C-fiber neurons. In the spinal dorsal horn, GIRK1- and −2-positive cell bodies and processes were mainly observed in lamina II, but also in superficial and deeper layers. Abundant GIRK1-, but not GIRK2-like immunoreactivity, was found in the ventral horn (laminae VI–X). Fourteen days after axotomy, GIRK1 and GIRK2 were down-regulated in DRG neurons at the mRNA and protein levels. Both after axotomy and rhizotomy there was a reduction of GIRK1- and −2-positive processes in the dorsal horn, suggesting a presynaptic localization of these potassium channels. Furthermore, nerve ligation caused accumulation of both subunits on both sides of the lesion, providing evidence for anterograde and retrograde fast axonal transport. Conclusions: Our data support the hypothesis that reduced GIRK function is associated with increased neuronal excitability and causes sensory disturbances in post-injury conditions, including neuropathic pain.
- 1 January 2015
- Published by SAGE Publications in Molecular Pain
- Vol. 11, 44
Open AccessG Protein-Gated Inwardly Rectifying Potassium Channel Subunits 1 and 2 are Down-Regulated in Rat Dorsal Root Ganglion Neurons and Spinal Cord after Peripheral Axotomy
Background: Increased nociceptive neuronal excitability underlies chronic pain conditions. Various ion channels, including sodium, calcium and potassium channels have pivotal roles in the control of neuronal excitability. The members of the family of G protein-gated inwardly rectifying potassium (GIRK) channels, GIRK1–4, have been implicated in modulating excitability. Here, we investigated the expression and distribution of GIRK1 and GIRK2 in normal and injured dorsal root ganglia (DRGs) and spinal cord of rats. Results: We found that ~70% of the DRG neurons expressed GIRK1, while only <10% expressed GIRK2. The neurochemical profiles of GIRK1- and GIRK2-immunoreactive neurons were characterized using the neuronal markers calcitonin gene-related peptide, isolectin-B4 and neurofilament-200, and the calcium-binding proteins calbindin D28k, calretinin, parvalbumin and secretagogin. Both GIRK subunits were expressed in DRG neurons with nociceptive characteristics. However, while GIRK1 was widely expressed in several sensory neuronal subtypes, GIRK2 was detected mainly in a group of small C-fiber neurons. In the spinal dorsal horn, GIRK1- and −2-positive cell bodies and processes were mainly observed in lamina II, but also in superficial and deeper layers. Abundant GIRK1-, but not GIRK2-like immunoreactivity, was found in the ventral horn (laminae VI–X). Fourteen days after axotomy, GIRK1 and GIRK2 were down-regulated in DRG neurons at the mRNA and protein levels. Both after axotomy and rhizotomy there was a reduction of GIRK1- and −2-positive processes in the dorsal horn, suggesting a presynaptic localization of these potassium channels. Furthermore, nerve ligation caused accumulation of both subunits on both sides of the lesion, providing evidence for anterograde and retrograde fast axonal transport. Conclusions: Our data support the hypothesis that reduced GIRK function is associated with increased neuronal excitability and causes sensory disturbances in post-injury conditions, including neuropathic pain.
- Open Access
- 1 January 2014
- Published by SAGE Publications in Molecular Pain
- Vol. 10, 12
Somatostatin and its 2A Receptor in Dorsal Root Ganglia and Dorsal Horn of Mouse and Human: Expression, Trafficking and Possible Role in Pain
Background: Somatostatin (SST) and some of its receptor subtypes have been implicated in pain signaling at the spinal level. In this study we have investigated the role of SST and its sst2A receptor (sst2A) in dorsal root ganglia (DRGs) and spinal cord.Results: SST and sst2A protein and sst2 transcript were found in both mouse and human DRGs, sst2A-immunoreactive (IR) cell bodies and processes in lamina II in mouse and human spinal dorsal horn, and sst2A-IR nerve terminals in mouse skin. The receptor protein was associated with the cell membrane. Following peripheral nerve injury sst2A-like immunoreactivity (LI) was decreased, and SST-LI increased in DRGs. sst2A-LI accumulated on the proximal and, more strongly, on the distal side of a sciatic nerve ligation. Fluorescence-labeled SST administered to a hind paw was internalized and retrogradely transported, indicating that a SST-sst2A complex may represent a retrograde signal. Internalization of sst2A was seen in DRG neurons after systemic treatment with the sst2 agonist octreotide (Oct), and in dorsal horn and DRG neurons after intrathecal administration. Some DRG neurons co-expressed sst2A and the neuropeptide Y Y1 receptor on the cell membrane, and systemic Oct caused co-internalization, hypothetically a sign of receptor heterodimerization. Oct treatment attenuated the reduction of pain threshold in a neuropathic pain model, in parallel suppressing the activation of p38 MAPK in the DRGsConclusions: The findings highlight a significant and complex role of the SST system in pain signaling. The fact that the sst2A system is found also in human DRGs and spinal cord, suggests that sst2A may represent a potential pharmacologic target for treatment of neuropathic pain.
- 1 January 2014
- Published by SAGE Publications in Molecular Pain
- Vol. 10, 12
Open AccessSomatostatin and its 2A Receptor in Dorsal Root Ganglia and Dorsal Horn of Mouse and Human: Expression, Trafficking and Possible Role in Pain
Background: Somatostatin (SST) and some of its receptor subtypes have been implicated in pain signaling at the spinal level. In this study we have investigated the role of SST and its sst2A receptor (sst2A) in dorsal root ganglia (DRGs) and spinal cord.Results: SST and sst2A protein and sst2 transcript were found in both mouse and human DRGs, sst2A-immunoreactive (IR) cell bodies and processes in lamina II in mouse and human spinal dorsal horn, and sst2A-IR nerve terminals in mouse skin. The receptor protein was associated with the cell membrane. Following peripheral nerve injury sst2A-like immunoreactivity (LI) was decreased, and SST-LI increased in DRGs. sst2A-LI accumulated on the proximal and, more strongly, on the distal side of a sciatic nerve ligation. Fluorescence-labeled SST administered to a hind paw was internalized and retrogradely transported, indicating that a SST-sst2A complex may represent a retrograde signal. Internalization of sst2A was seen in DRG neurons after systemic treatment with the sst2 agonist octreotide (Oct), and in dorsal horn and DRG neurons after intrathecal administration. Some DRG neurons co-expressed sst2A and the neuropeptide Y Y1 receptor on the cell membrane, and systemic Oct caused co-internalization, hypothetically a sign of receptor heterodimerization. Oct treatment attenuated the reduction of pain threshold in a neuropathic pain model, in parallel suppressing the activation of p38 MAPK in the DRGsConclusions: The findings highlight a significant and complex role of the SST system in pain signaling. The fact that the sst2A system is found also in human DRGs and spinal cord, suggests that sst2A may represent a potential pharmacologic target for treatment of neuropathic pain.
- Open Access
- 29 July 2013
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 24 (12) , 3277-3288
GABAergic Terminals Are a Source of Galanin to Modulate Cholinergic Neuron Development in the Neonatal Forebrain
The distribution and (patho-)physiological role of neuropeptides in the adult and aging brain have been extensively studied. Galanin is an inhibitory neuropeptide that can coexist with γ-aminobutyric acid (GABA) in the adult forebrain. However, galanin's expression sites, mode of signaling, impact on neuronal morphology, and colocalization with amino acid neurotransmitters during brain development are less well understood. Here, we show that galaninergic innervation of cholinergic projection neurons, which preferentially express galanin receptor 2 (GalR2) in the neonatal mouse basal forebrain, develops by birth. Nerve growth factor (NGF), known to modulate cholinergic morphogenesis, increases GalR2 expression. GalR2 antagonism (M871) in neonates reduces the in vivo expression and axonal targeting of the vesicular acetylcholine transporter (VAChT), indispensable for cholinergic neurotransmission. During cholinergic neuritogenesis in vitro, GalR2 can recruit Rho-family GTPases to induce the extension of a VAChT-containing primary neurite, the prospective axon. In doing so, GalR2 signaling dose-dependently modulates directional filopodial growth and antagonizes NGF-induced growth cone differentiation. Galanin accumulates in GABA-containing nerve terminals in the neonatal basal forebrain, suggesting its contribution to activity-driven cholinergic development during the perinatal period. Overall, our data define the cellular specificity and molecular complexity of galanin action in the developing basal forebrain.
- 29 July 2013
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 24 (12) , 3277-3288
Open AccessGABAergic Terminals Are a Source of Galanin to Modulate Cholinergic Neuron Development in the Neonatal Forebrain
The distribution and (patho-)physiological role of neuropeptides in the adult and aging brain have been extensively studied. Galanin is an inhibitory neuropeptide that can coexist with γ-aminobutyric acid (GABA) in the adult forebrain. However, galanin's expression sites, mode of signaling, impact on neuronal morphology, and colocalization with amino acid neurotransmitters during brain development are less well understood. Here, we show that galaninergic innervation of cholinergic projection neurons, which preferentially express galanin receptor 2 (GalR2) in the neonatal mouse basal forebrain, develops by birth. Nerve growth factor (NGF), known to modulate cholinergic morphogenesis, increases GalR2 expression. GalR2 antagonism (M871) in neonates reduces the in vivo expression and axonal targeting of the vesicular acetylcholine transporter (VAChT), indispensable for cholinergic neurotransmission. During cholinergic neuritogenesis in vitro, GalR2 can recruit Rho-family GTPases to induce the extension of a VAChT-containing primary neurite, the prospective axon. In doing so, GalR2 signaling dose-dependently modulates directional filopodial growth and antagonizes NGF-induced growth cone differentiation. Galanin accumulates in GABA-containing nerve terminals in the neonatal basal forebrain, suggesting its contribution to activity-driven cholinergic development during the perinatal period. Overall, our data define the cellular specificity and molecular complexity of galanin action in the developing basal forebrain.